SEARCH

SEARCH BY CITATION

References

  • 1
    Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595600.
  • 2
    Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601607.
  • 3
    Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J et al. (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76, 672680.
  • 4
    Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP & Gallo KA (2006) LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci 29, 286293.
  • 5
    Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP et al. (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365, 415416.
  • 6
    Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 365, 410412.
  • 7
    Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N et al. (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 365, 412415.
  • 8
    West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL & Dawson TM (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102, 1684216847.
  • 9
    Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM & Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 12311233.
  • 10
    Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329341.
  • 11
    MacLeod D, Dowman J, Hammond R, Leete T, Inoue K & Abeliovich A (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587593.
  • 12
    Plowey ED, Cherra SJ III, Liu YJ & Chu CT (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105, 10481056.
  • 13
    Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O’Neill E, Meitinger T, Kolch W, Prokisch H & Ueffing M (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15, 223232.
  • 14
    Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A & Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. Biochem J 405, 307317.
  • 15
    West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL et al. (2007) Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223232.
  • 16
    Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL & Chen SG (2007) The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313, 36583670.
  • 17
    Luzon-Toro B, de la Torre ER, Delgado A, Perez-Tur J & Hilfiker S (2007) Mechanistic insight into the dominant mode of the Parkinson’s disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16, 20312039.
  • 18
    Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E & Lu B (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27, 24322443.
  • 19
    Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM & Ross CA (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci USA 102, 1867618681.
  • 20
    Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28, 33843391.
  • 21
    Gandhi PN, Wang X, Zhu X, Chen SG & Wilson-Delfosse AL (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86, 17111720.
  • 22
    Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A et al. (2008) The Parkinson’s disease associated leucine rich repeat kinase 2 (LRRK2) is a dimer that undergoes intra-molecular autophosphorylation. J Biol Chem 283, 1690616914.
  • 23
    Johnson LN, Noble ME & Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85, 149158.
  • 24
    Wang ZX & Wu JW (2002) Autophosphorylation kinetics of protein kinases. Biochem J 368, 947952.
  • 25
    Furdui CM, Lew ED, Schlessinger J & Anderson KS (2006) Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21, 711717.
  • 26
    Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A & Gambacorti-Passerini C (2005) Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expr Purif 41, 177185.
  • 27
    Manning G, Whyte DB, Martinez R, Hunter T & Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 19121934.
  • 28
    Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T & Iwatsubo T (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson’s disease. Biochemistry 46, 13801388.
  • 29
    Li X, Tan YC, Poulose S, Olanow CW, Huang XY & Yue Z (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants. J Neurochem 103, 238247.
  • 30
    Giasson BI & Van Deerlin VM (2008) Mutations in LRRK2 as a cause of Parkinson’s disease. Neurosignals 16, 99105.
  • 31
    Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V & Pezzoli G (2007) Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 68, 11411143.
  • 32
    Pimentel MM, Moura KC, Abdalla CB, Pereira JS, Rosso AL, Nicaretta DH, Junior MC, Almeida RM, Santos JM, Bastos IC et al. (2007) A study of LRRK2 mutations and Parkinson’s disease in Brazil. Neurosci Lett 433, 1721.